Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029061 | 1.00 | HTR2C (0.37) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3031802 | 1.00 | HTR2C (0.37) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3029064 | 1.00 | HTR2C (0.37) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3029067 | 1.00 | HTR2C (0.37) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL8066901 | 0.89 | HTR3A (0.36) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3020374 | 0.89 | HTR3A (0.36) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3024829 | 0.89 | HTR3A (0.36) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3024830 | 0.89 | HTR3A (0.36) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3020369 | 0.89 | HTR3A (0.36) | HTR2CHTR2AHTR2BSLC6A4SLC6A2 | |
| SCHEMBL3025062 | 0.84 | HTR3A (0.33) | HTR2CSLC6A4SLC6A2HTR3ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | HTR2C 2/4885HTR2A 10/4885HTR2B 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.